Therapeutic resistance leading to tumor relapse is a major challenge in breast cancer (BCa)
treatment. Numerous factors involved in multiple mechanisms promote the development of …

In this study, we investigated the effects and the underlying molecular mechanisms of the
multi-kinase inhibitor sorafenib in a panel of breast cancer cell lines. Sorafenib inhibited cell …

Background Prostate cancer (PCa) is a progressive disease and the most diagnosed cancer
in men. The current standard of care for high‐risk localized PCa is a combination of …

Background and purpose There is a great need to improve the outcome of locoregionally
advanced squamous cell carcinomas of the head and neck (HNSCC). Standard treatment …

Despite efforts to improve surgical, radiologic, and chemotherapeutic strategies, the
outcome of patients with glioblastoma (GBM) is still poor. Polo-like kinase 1 (PLK1) is a …

Background aims Mesenchymal stromal cells (MSCs) have been used to minimize and
repair radiation-induced normal tissue injury in the intestine, salivary gland, liver, skin, lungs …

Despite the improvements in neoadjuvant chemotherapy, the outcome of patients with
advanced bladder cancer has changed very little over the past 30 years. In the present study …

Oesophageal cancer is the sixth cause of cancer-related death worldwide. Nowadays
radiochemotherapy (RTCT) plays a central role in the treatment settings of such disease …

Despite aggressive chemoradiation (CRT) protocols in the treatment of patients with head
and neck squamous cell carcinomas (HNSCC), the outcome is still unfavorable. To improve …

Purpose: Sorafenib, an oral multikinase inhibitor, is the first agent that has demonstrated an
improved overall survival benefit in advanced hepatocellular carcinoma, setting a new …